Clinical trials: Obstructive Pulmonary Diseases
Asthma
Asthma Control Test Guided Treatment in Chinese Subjects
This study is aimed to evaluate the effectiveness of Asthma Control Test (ACT) guided treatment compared with usual care in asthma subjects in China.
- Trial name
- NCT02868281
- Testing
- ACT guided Routine Treatment, Routine Treatment
- Where
- 6 sites in China
- Volunteers
- 530 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks.
- Trial name
- NCT00079937
- Testing
- Omalizumab, Fluticasone
- Where
- 56 sites in United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a 12-week, multicentre, randomized, open-label, 2-arm, parallel-group study designed to compare the efficacy and safety of umeclidinium inhalation powder (62.5 mcg once daily [QD]) administered via a novel Dry Powder…
- Trial name
- NCT02236611
- Testing
- Umeclidinium, Glycopyrronium
- Where
- 94 sites in Argentina, Chile and 8 more
- Volunteers
- 1,036 people
- Sponsor
- GlaxoSmithKline
B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
This is a Phase II, open-label, prospective, multicenter study to evaluate the efficacy and safety of subcutaneously administered alemtuzumab (CAMPATH, MabCampath) as therapy for patients with relapsed or refractory B-CLL who…
- Trial name
- NCT00328198
- Testing
- Alemtuzumab
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 86 people
- Sponsor
- Genzyme, a Sanofi Company
Asthma, Bronchial
Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults
This study is intended to extend the knowledge of Symbicort Single Inhaler Therapy into a more general setting in order to assess the real-life impact of introducing this new treatment concept.
- Trial name
- NCT00385593
- Testing
- Symbicort (budesonide/formoterol) Turbuhaler, Conventional treatment
- Where
- 52 sites in Spain
- Volunteers
- 654 people
- Sponsor
- AstraZeneca
Lung Diseases, Sleep Apnea Syndromes
Continuous Positive Airway Pressure to Improve Milder Obstructive Sleep Apnea
The purpose of this study is to determine whether functional status improves in individuals with milder obstructive sleep apnea (OSA) following continuous positive airway pressure (CPAP) treatment.
- Conditions
- Lung Diseases, Sleep Apnea Syndromes, Hypertension
- Trial name
- CATNAP (NCT00089752)
- Testing
- Continuous Positive Airway Pressure (CPAP) Treatment
- Where
- 5 sites in United States, Canada
- Volunteers
- 281 people
- Sponsor
- University of Pennsylvania
Pulmonary Disease, Chronic Obstructive
Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients
The present study is planned to evaluate the effect of the aclidinium bromide/formoterol fumarate 400/12 μg FDC BID on the hyperinflation, exercise endurance and physical activity in patients with moderate to severe COPD.
- Trial name
- ACTIVATE (NCT02424344)
- Testing
- Aclidinium/Formoterol
- Where
- 26 sites in Canada, Germany and 2 more
- Volunteers
- 267 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD
This study will evaluate the efficacy and safety of QVA149 (110/50 μg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD
- Trial name
- NCT02603393
- Testing
- QVA149, Tiotropium, Salmeterol/fluticasone
- Where
- 167 sites in Argentina, Austria and 19 more
- Volunteers
- 1,053 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
The objective of the trial is to compare the lung function profile of once daily treatment with tiotropium+olodaterol FDC [2.5/ 5µg and 5/ 5µg] delivered by the RESPIMAT with the lung function profile of twice daily treatment…
- Trial name
- NCT01969721
- Testing
- fluticasone propionate, salmeterol, tiotropium
- Where
- 29 sites in Belgium, Czechia and 6 more
- Volunteers
- 229 people
- Sponsor
- Boehringer Ingelheim
Asthma
Teva Asthma Predictive Analytics Study
This trial is being completed to determine baseline inhalation parameters and patterns of use in patients receiving treatment with TEVA digital inhalers, to develop predictive models for asthma exacerbations and response to…
- Trial name
- NCT04997304
- Testing
- AirDuo Digihaler, ProAir Digihaler
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Michigan
Hepatitis C Virus Infection
Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 8 weeks and of treatment with…
- Trial name
- POLARIS-3 (NCT02639338)
- Testing
- SOF/VEL/VOX, SOF/VEL
- Where
- 70 sites in United States, Australia and 6 more
- Volunteers
- 220 people
- Sponsor
- Gilead Sciences
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks
The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticanse propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to…
- Trial name
- NCT01772134
- Testing
- Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg
- Where
- 73 sites in United States, Canada and 2 more
- Volunteers
- 617 people
- Sponsor
- GlaxoSmithKline
Asthma
An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma
The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration(FDA)) in the Hispanic population.
- Trial name
- NCT00419757
- Testing
- Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 558 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Seasonal, Asthma
Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)
This study will compare mometasone nasal spray to placebo in treating the nasal and asthma symptoms experienced by participants with seasonal allergic rhinitis (SAR) and concomitant asthma.
- Trial name
- NCT00070707
- Testing
- Mometasone, Albuterol/Salbutamol
- Volunteers
- 188 people
- Sponsor
- Organon and Co
Asthma
Bosentan for Poorly Controlled Asthma
Hypothesis: The endothelin-1 receptor antagonist, bosentan when added to the treatment of asthma patients who are symptomatic despite the use of controller therapy will improve asthma symptoms and physiology.
- Trial name
- NCT00815347
- Testing
- bosentan
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- UConn Health
CHF, COPD
A Technology Assisted Care Transition Intervention for Veterans With CHF or COPD
Transition from hospital to home places patients in jeopardy of adverse events and increases their risk for rehospitalization. CHF is the most prevalent chronic condition among U.S.
- Trial name
- TACT (NCT02632552)
- Testing
- Technology-assisted care transition intervention, Active attention control
- Where
- 5 sites in United States
- Volunteers
- 140 people
- Sponsor
- VA Office of Research and Development
Cystic Fibrosis
A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations
This study investigates the use of cysteamine in the treatment of adults with Cystic Fibrosis who are experiencing an exacerbation of CF-associated lung disease.
- Trial name
- CARE-CF1 (NCT03000348)
- Testing
- Cysteamine
- Where
- 17 sites in United States, Italy and 1 more
- Volunteers
- 91 people
- Sponsor
- NovaBiotics Ltd.
Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306…
- Trial name
- NCT02334748
- Testing
- canakinumab
- Where
- 3 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study Of RV-39 In Patients Who Also Have Asthma
This study will last up to 9 weeks. Subjects will visit the clinic up to 14 times. Certain clinic visits will include a physical examination, lung function tests, inflammatory cell analysis from nasal secretions and/or sputum…
- Trial name
- NCT00503009
- Testing
- fluticasone propionate/salmeterol, fluticasone propionate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD), Heart Failure
An Intervention to Improve Function in Severe Cardiopulmonary Illness
The study is a randomized trial of a cardiopulmonary self-management intervention to improve functional capacity, health-related quality of life, and to reduce health care utilization.
- Trial name
- NCT00467298
- Testing
- Exercise adherence, Self-management- prevention of illness, Self-management of illness
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- VA Office of Research and Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.